Dofetilide: A new pure class III antiarrhythmic agent

American Heart Journal

Volumn 140, Issue 5, 2000, Pages 697-706

  Falk, Rodney H ^a   DeCara, Jeanne M ^a  

^a BOSTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; DOFETILIDE; PLACEBO; POTASSIUM CHANNEL BLOCKING AGENT; WARFARIN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG APPROVAL; DRUG EFFICACY; DRUG EXCRETION; DRUG SAFETY; ELECTROPHYSIOLOGY; FEMALE; FOOD AND DRUG ADMINISTRATION; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART EJECTION FRACTION; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE FUNCTION; HUMAN; INOTROPISM; MAJOR CLINICAL STUDY; MALE; MORTALITY; POTASSIUM CURRENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TORSADE DES POINTES; URINARY EXCRETION;

EID: 0033755302     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2000.110457     Document Type: Article

References (57)

1. Voltage- and time-dependent block of the delayed K+ current in cardiac myocytes by dofetilide
2. UK-68,798: A novel, potent and highly selective class III antiarrhythmic agent which blocks potassium channels in cardiac cells
3. Differential effects of the new class III agent dofetilide on potassium currents in guinea pig cardiomyocytes
4. Rate and concentration-dependent effects of UK-68,798, a potent new class III antiarrhythmic, on canine Purkinje fibre action potential duration and Vmax
5. Pharmacokinetic and pharmacodynamic modeling of the effects of oral and intravenous administrations of dofetilide on ventricular repolarization
6. Pharmacokinetic and pharmacodynamic effects of UK-68,798, a new potential class III antiarrhythmic drug
7. Pharmacokinetics and metabolism of dofetilide in mouse, rat, dog and man
8. Pharmacodynamics and pharmacokinetics of the class III antiarrhythmic agent dofetilide (UK-68,798) in humans
9. Significance of metabolism in the disposition and action of the antidysrhythmic drug, dofetilide. In vitro studies and correlation with in vivo data
10. Electropharmacology of dofetilide, a new class III agent, in anaesthetised dogs
11. Differential atrial versus ventricular activities of class III potassium channel blockers
12. Effects of dofetilide, a class III antiarrhythmic drug, on various ventricular arrhythmias in dogs
13. Dofetilide reduces the incidence of ventricular fibrillation during acute myocardial ischaemia. A randomised study in pigs
14. Effects of the class III antiarrhythmic drug dofetilide on ventricular monophasic action potential duration and QT interval dispersion in stable angina pectoris
15. Clinical and electrophysiologic effects of dofetilide in patients with supraventricular tachyarrhythmias
16. Effects of the novel antiarrhythmic agent azimilide on experimental atrial fibrillation and atrial electrophysiologic properties
17. A dose-ranging study of UK-68,798, a novel class III anti-arrhythmic agent, in normal volunteers
18. Influence of dofetilide on QT-interval duration and dispersion at various heart rates during exercise in humans
19. Effects of altered extracellular potassium and pacing cycle length on the class III antiarrhythmic actions of dofetilide (UK-68,798) in guinea-pig papillary muscle
20. Cellular electrophysiology of WAY-123,398, a new class III antiarrhythmic agent: Specificity of IK block and lack of reverse use dependence in cat ventricular myocytes
21. Use-dependent block of the delayed K+ current in rabbit ventricular myocytes
22. Voltage dependence of cardiac delayed rectifier block by methanesulfonamide class III antiarrhythmic agents
23. Electrophysiologic profile and efficacy of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with sustained monomorphic ventricular tachycardia. Dofetilide Arrhythmia Study Group
24. Assessment of reverse use-dependent blocking actions of class III antiarrhythmic drugs by 24-hour Holter electrocardiography
25. Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence
26. Differential rate and potassium dependent effects of class III agents d-sotalol and dofetilide on guinea pig papillary muscle
27. Dynamic analysis of dofetilide-induced changes in ventricular repolarization
28. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators
29. Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: A multicenter, randomized, double-blind, placebo-controlled trial
30. Exaggerated QT prolongation after cardioversion of atrial fibrillation
31. Pause-dependent polymorphic VT during long-term treatment with dofetilide: A placebo-controlled study
32. Efficacy and safety of oral dofetilide in patients with an implanted defibrillator: A multicenter study
33. Effects of new and potent methanesulfonanilide class III antiarrhythmic agents on myocardial refractoriness and contractility in isolated cardiac muscle
34. Rate-dependent class III antiarrhythmic action, negative chronotropy, and positive inotropy of a novel Ik blocking drug, UK-68,798: Potent in guinea pig but no effect in rat myocardium
35. Cardiac electrophysiologic and inotropic actions of new and potent methanesulfonanilide class III antiarrhythmic agents in anesthetized dogs
36. Positive atrial inotropic effect of dofetilide following cardioversion of atrial fibrillation or flutter
37. Negative chronotropic effect of a novel class III antiarrhythmic drug, UK-68,798, devoid of beta-blocking action on isolated guinea-pig atria
38. Intravenous therapy for atrial fibrillation: More choices, more questions, more trials
39. Conversion of atrial fibrillation and maintenance of sinus rhythm by dofetilide. The EMERALD (European and Australian Multicenter Evaluative Research on Atrial Fibrillation Dofetilide) study
40. Meeting highlights: Highlights of the 71st Scientific Sessions of the American Heart Association
41. Efficacy and safety of oral dofetilide in maintaining normal sinus rhythm in patients with atrial fibrillation/flutter: A multicenter study
42. Oral dofetilide for conversion of patients with chronic atrial fibrillation or atrial flutter to normal sinus rhythm: A multicenter study
43. Oral dofetilide for conversion of atrial fibrillation/flutter to sinus rhythm: Time to cardioversion and duration of hospital stay
44. Efficacy and safety of oral dofetilide in maintaining sinus rhythm: 12 months follow-up results of SAFIRE-D
45. The efficacy and safety of dofetilide in the prevention of symptomatic attacks of paroxysmal supraventricular tachycardia
46. Effect of ecainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction
47. Effect of d-sotalol on mortality in patient with left ventricular dysfunction after recent and remote myocardial infarction
48. Dofetilide in patients with left ventricular dysfunction and either heart failure or acute myocardial infarction: Rationale, design, and patient characteristics of the DIAMOND studies
49. Dofetilide in patients with congestive heart failure and left ventricular dysfunction
50. Meeting highlights: Highlights of the 70th Scientific Sessions of the American Heart Association
51. Session highlights from the American Heart Association Scientific Sessions: November 9-12, 1997
52. A clinical trial of dofetilide in patients with acute myocardial infarction and left ventricular dysfunction: The DIAMOND MI study
53. Mortality in the survival with oral d-sotalol trial: Why did patients die?
54. Effect of dofetilide on survival in patients with supraventricular arrhythmias
55. Dofetilide improves quality of life
56. The effect of dofetilide on pharmacodynamics of warfarin and pharmacokinetics of digoxin
57. Amiodarone to prevent recurrence of atrial fibrillation